Last reviewed · How we verify
Centre d'Appui à la lutte contre la Maladie — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| ''albendazole'' and ''ivermectin'' | ''albendazole'' and ''ivermectin'' | marketed | Antihelmintic/Antiparasitic agents | β-tubulin (albendazole); glutamate-gated chloride channels (ivermectin) | Infectious Disease / Parasitology |
Therapeutic area mix
- Infectious Disease / Parasitology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Centre d'Appui à la lutte contre la Maladie:
- Centre d'Appui à la lutte contre la Maladie pipeline updates — RSS
- Centre d'Appui à la lutte contre la Maladie pipeline updates — Atom
- Centre d'Appui à la lutte contre la Maladie pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Centre d'Appui à la lutte contre la Maladie — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/centre-d-appui-la-lutte-contre-la-maladie. Accessed 2026-05-17.